Navigation Links
ProMetic provides business update - Over $35 million worth of business secured in January
Date:2/6/2008

e,

representing annual recurring revenue of $5 M. The initial five-

year supply agreement is in final stage of negotiation with

commercial quantities of resin supply commencing as soon as mid-

2008, following regulatory approval of the product.

- The Food and Drug Administration ("FDA") has granted approval to

Zymogenetics, Inc. for the commercial sale of Recothrom(R) a

recombinant thrombin product which is manufactured using a synthetic-

ligand affinity adsorbent supplied by ProMetic. This is one of ten

licenced products that have now been approved for sale by the FDA

and/or the European Medicines Agency ("EMEA") which uses ProMetic's

purification technology as part of their manufacture or function.

- Improved sensitivity by 80-fold of existing diagnostic devices was

achieved by pre-treating the samples with PRDT's enhanced concentration

technology. The results showed an added level of sensitivity to the BSE

detection process, thereby reducing the risk of "false outcomes" with

existing tests. This could allow for the detection of infectious prions

at an earlier phase in the development of the disease, thus improving

the safety of the food industry for the countries testing for BSE.

A more comprehensive update for PBI-1402 will be provided shortly as the Company is pursuing its clinical development and as partnership discussions are accelerating.

About ProMetic Life Sciences Inc.

ProMetic Life Sciences Inc. (http://www.prometic.com) is a biopharmaceutical company specialized in the research, development, manufacture and marketing of a variety of commercial applications derived from its proprietary Mimetic Ligand(TM) technology. This technology is used in large-scale purification of biologics and the elimination of pathogens. ProMetic is als
'/>"/>

SOURCE PROMETIC LIFE SCIENCES INC.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. ProMetic announces scale-up of prion removal resin in plasma product for biopharmaceutical use
2. ProMetic and MacoPharma announce successful completion of P-Capt(R) prion reduction filter clinical studies
3. Thermo Fisher Scientific Reports Record 2007 Fourth Quarter Revenues and Operating Performance; Provides Guidance for 2008
4. Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application
5. Amarin Provides Business Update and Announces Implementation of Reverse Stock Split
6. YM BioSciences provides update on AeroLEF(TM) clinical development program
7. ViroPharma Provides 2008 Outlook
8. Evotec Provides Update on Planned NASDAQ Listing in the Context of its Announced Acquisition of Renovis
9. Cinpathogen Provides Clinical Diagnostic Consulting Services to Shanghai Area Hospitals
10. Strativa Pharmaceuticals, the Proprietary Products Division of Par Pharmaceutical, Provides an Update on Development Status of Pafuramidine and Other in-Licensed Products
11. Survey of More than 600 Patients Treated with Tracleer(R) (bosentan) Reveals Actelion Sure Steps(R) Patient Support Program Provides Valuable Educational Information
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)...re/ -- The world,s first concept demonstration t...ugh alternative to replace a petrochemically produ...ber with renewable biomass, made their debut in Co...display at a lounge in the common departure area a...December 21, while the other tire will make appear...
(Date:12/2/2009)...swire-FirstCall/ - Oncolytics Biotech Inc. ("Oncol...announced today that in connection with its previo...e exercised in full their over-allotment option an... is comprised of one common share and 0.4 of a com...e of US$3.00 per unit. Each whole common share pur...
(Date:12/2/2009)...s, December 2 Pepscan Holding NV,...ng on protein mimicking,technology for the generat...,has appointed Wim E.M. Mol, Ph.D. as new Chief Ex...sible for all of Pepscans corporate functions and,...the company. He brings to,Pepscan more than 20 yea...
(Date:12/2/2009)... December 2 Gamida Cell announced ...al (animal study) safety and,efficacy of a gene th...,Cornell Medical College and Gamida Cell. The prod...such as Cooley,s Anemia. , Gamida Cell is... vivo,populations of stem/progenitor cells. The c...
Breaking Biology Technology:The World's First Goodyear Concept Tires Made with BioIsoprene(TM) Technology Arrive in Copenhagen in time for United Nations Climate Change Conference 2The World's First Goodyear Concept Tires Made with BioIsoprene(TM) Technology Arrive in Copenhagen in time for United Nations Climate Change Conference 3Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 2Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 3Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 4Dutch Biotech Company Pepscan Appoints New CEO 2Gamida Cell Announces Feasibility Study With Weill Cornell Medical College 2Gamida Cell Announces Feasibility Study With Weill Cornell Medical College 3
...today,announced the appointment of industry vetera... further bolstering its position as a leader in th...Mr. Bailye, 54, recently retired from his position... Dendrite was acquired by French information,provi...te, a pharmaceutical,sales force automation system...
...HERAL VASCULAR DEVICE MARKET INSIGHTS WEBINAR ... Thursday, June 5, 2008, 11 am US Eastern Ti...s), PRESENTER: Stephanie LaBelle, Analyst from ...e the link below to register or call Shiu-Yik Au a...Research Group presents a complimentary Webinar ou...
...ire-FirstCall/ - Quest PharmaTech Inc. (TSX-V:,QPT...t its 12-patient,Phase I clinical study entitled "...todynamic Therapy of Actinic Keratosis" has met bo...re delighted to have received, for the first time,...in a dermatological application,",said Madi R. Mad...
Other Biology Technology:IntegriChain Appoints John Bailye to Its Board of Directors 2Peripheral Vascular Device Market Insights Webinar 2Quest PharmaTech Announces Positive Results from Phase I Clinical Trial of its Photodynamic Therapy for Actinic Keratosis 2Quest PharmaTech Announces Positive Results from Phase I Clinical Trial of its Photodynamic Therapy for Actinic Keratosis 3
(Date:12/3/2009)... investment in energy efficient technologies resea...h Council (EPSRC) Chief Executive Dave Delpy belie...ng research has already brought us fuel cells, mar...stment is needed to develop the capabilities of di...ssion targets by 2020 and limit the impact of clim...
(Date:12/2/2009)...ino men have a more difficult time quitting smokin...ture, but acculturation has no affect on Latinas o... are published in Cancer Epidemiology, Biomarkers...ion for Cancer Research. The December issue has a ...ts smoking cessation differently for Latino men an...
(Date:12/2/2009)...cents exposed to cigarette smoking scenes in movie... and this may be part of the acculturation process...new study findings. , "Our study supports an R-r...hts the global implementation of the World Health ...ol, which includes guidelines for countries to res...
Breaking Biology News(10 mins):Research is vital to a cleaner, greener, low carbon future 2Acculturation affects smoking cessation success among Latinos 2Watching movies featuring characters who smoke negatively influences Mexican-American teens 2Pharmacyclics to Host Webcast and Conference Call to Discuss Clinical Updates on Its HDAC and BTK Program as Presented at The American Society of Hema 6741 1Pharmacyclics to Host Webcast and Conference Call to Discuss Clinical Updates on Its HDAC and BTK Program as Presented at The American Society of Hema 6741 2Blood Clot Threat After Surgery Worse Than Thought 62571 1Blood Clot Threat After Surgery Worse Than Thought 62571 2Blood Clot Threat After Surgery Worse Than Thought 62571 3Blood Sugar Intolerance May Predict Postpartum Ills 62567 1Blood Sugar Intolerance May Predict Postpartum Ills 62567 2
...TON, DC -- Sweetpotatoes, often misunderstood and ...saving food crop in developing countries. , Accor...tato.org ), more than 95 percent of the global swe...ere it is the fifth most important food crop. Desp...e potato. Potatoes are tubers (referring to their ...
...ts have identified a new way to breed brassicas, w...esistant to a damaging virus. Their discovery has ... be durable, broad-spectrum and unlikely to be ove...(TuMV) is an economically devastating virus that i...cially brassicas. In research published recently i...
...ama Barkai will receive the Helen and Martin Kimme...v. 5 at the Weizmann Institute. The award is accom...er five years. , Taking a chance on an experiment.... Living cells are, from this angle, great subject... have all sorts of interesting consequences for ma...
Other Biology News:Sweet potato shines as new promise for small enterprise and hunger relief in developing countries 2Sweet potato shines as new promise for small enterprise and hunger relief in developing countries 3Genes identified to protect brassicas from damaging disease 2Weizmann Institute scientists discover: A 'risk distribution law' for evolution 2
Biolase Core Kit from Bioline
...amplification of GC-rich nucleic acids ,The GC-... a proofreading polymerase, powers through templat...h other polymerases and other blends of polymerase...unique GC-RICH Resolution Solution combine to deli...
...nogen: synthetic peptide corresponding to the thir..., conjugated to KLH. The immunizing peptide has 79...form: Solution in phosphate buffered saline, pH 7....d: IHC (p). Titertest values: immunohistochemistr...
CnC (Cn402-05) from European Collection of Cell Cultures (ECACC)
Biology Products: